Lung Cancer | Specialty

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24th 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Recent Progress in Squamous NSCLC and SCLC Moves Needle Forward

January 23rd 2019

Janakiraman Subramanian, MD, discusses ongoing advances and remaining challenges in the field of lung cancer.

Dr. Kujtan on Patient Preferences in the Treatment of NSCLC

January 23rd 2019

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses the importance of patient preferences in the treatment of oncogene-driven non-small cell lung cancer (NSCLC).

Expert Examines Emerging Biomarkers in NSCLC

January 22nd 2019

Brandon Weckbaugh, MD, sheds light on emerging biomarkers in non–small cell lung cancer.

Dr. Sabari Discusses Role of Immunotherapy in SCLC

January 18th 2019

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses the role of immunotherapy in the treatment of patients with small cell lung cancer.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC

January 17th 2019

Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.

FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

January 17th 2019

The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.

Navigating the Complex Paradigm of Oncogene-Driven NSCLC

January 16th 2019

Lara Kujtan, MD, sheds light on how to navigate the complex paradigm of oncogene-driven non–small cell lung cancer and stressed the importance of patient preferences when deciding on optimal treatment approaches.

Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC

January 16th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).

Sequencing Therapy in ALK+ NSCLC

January 14th 2019

Biopsy Considerations After Progression in ALK+ NSCLC

January 14th 2019

Treating Newly Diagnosed ALK+ NSCLC

January 14th 2019

Systemic Therapy Vs Radiotherapy for Small Brain Mets

January 14th 2019

Treatment of EGFR+ NSCLC After Osimertinib

January 14th 2019

Frontline Treatment for EGFR+ NSCLC

January 14th 2019

NSCLC: Treating Progression After Chemo and I-O

January 14th 2019

TMB and Multiplex Testing in Metastatic NSCLC

January 14th 2019

Combinations With Novel Agents for Metastatic NSCLC

January 14th 2019

Chemo + I-O in Frontline mNSCLC: PD-L1 TPS >50%

January 14th 2019